An advantage in favor of prulifloxacin prophylaxis emerged , according to EORTC QLQ-BLS24 , in overall incidence of nocturnal micturitions ( 56 % vs 28.6 % ; p = 0.001 ) , insomnia ( 40 % vs 14.3 % ; p = 0.002 ) , urgency ( 70 % vs 42.6 % ; p = 0.05 ) , incontinence ( 44 % vs 12.7 % ; p = 0.01 ) and bothersome events due to intravesical therapy ( 84 % vs 63.5 % ; p = 0.02 ) .
